SCHEMBL14256

SCHEMBL14256

NCc1ccc(-n2cc3cc(-c4cccc(CCN5CCNCC5)c4)[nH]c3nc2=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.40
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
VCP P55072 2/20 0.37
SIGMAR1 Q99720 2/20 0.36
IKBKB O14920 1/20 0.36
CHUK O15111 1/20 0.36
HTR1A P08908 3/20 0.35
DRD2 P14416 3/20 0.35
HTR2A P28223 3/20 0.35
CHRM3 P20309 3/20 0.35
HTR2C P28335 1/20 0.34
MAPK14 Q16539 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
BTK Q06187 1/20 0.34
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
PRMT5 O14744 1/20 0.33
TNKS O95271 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14517 0.92 CHRM3 (0.41) CHRM3BTKTNKS
SCHEMBL14469 0.84 CHRM3 (0.34) SLC6A4VCPCHRM3
SCHEMBL14104 0.84 CHUK (0.38) IKBKBCHUKMAPK14
SCHEMBL14361 0.79 ALDH1A1 (0.39) CHUK
SCHEMBL14038 0.77 GSK3B (0.37) IKBKBCHUK
SCHEMBL14369 0.76 CHRM3 (0.39) CHRM3
SCHEMBL14421 0.75 VCP (0.38) VCPHTR1AHRH4
SCHEMBL14187 0.75 IKBKB (0.35) IKBKBCHUK
SCHEMBL13814 0.75 CHUK (0.44) VCPIKBKBCHUKMAPK14
SCHEMBL13916 0.74 PDE3B (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488525-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-04-25 EP disclosed
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT SLC6A4 4116/4885SLC6A2 3776/4885SLC6A3 3237/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT SLC6A4 4116/4885SLC6A2 3776/4885SLC6A3 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.